

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

北 斗 嘉 藥 業 股 份 有 限 公 司
BAYTACARE PHARMACEUTICAL CO., LTD.*

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 8197)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) of Baytacare Pharmaceutical Co., Ltd.* (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Mr. Zhu Tianxiang has been appointed as an independent non-executive director of the Company with effect from 24 April 2019 until the date of the next annual general meeting of the Company. Mr. Zhu has also been appointed as the chairman of the Remuneration Committee, a member of the Audit Committee and a member of the Nomination Committee with effect from 24 April 2019 until the date of the next annual general meeting of the Company.

The biological details of Mr. Zhu are as follows:

Mr. Zhu Tianxiang, aged 46, graduated from the School of Accountancy of Jiangxi College of Finance and Economics with a degree in international accounting and securities investment. Mr. Zhu has extensive experience in financial management and possesses professional qualification in accounting. He served as a manager of financial department in various companies from August 1994 to July 2002. From December 2004 to June 2008, Mr. Zhu served as a senior management member, a member of the president office, the chief duty compliance officer and the vice president of Founder Securities Limited. Subsequently, Mr. Zhu occupied various important positions in Credit Suisse Founder Securities Limited such as financial controller and secretary to the board. In addition, Mr. Zhu also served as the group general manager of Shenzhen Dasheng Agricultural Group Co., Ltd.* (深圳市大生農業集團有限公司). Mr. Zhu once served as a director and general manager of Shangdong Jiangquan Company Limited* (山東江泉股份有限公司) and a non-executive director of Shanghai Dasheng Agriculture Finance Technology Co., Ltd. (formerly known as Shanghai Tonva Petrochemical Co., Ltd.) (Hong Kong listed company stock code: 1103). Mr. Zhu is currently an executive director of Sino Energy International Holdings Group Limited (Hong Kong listed company stock code: 1096).

Save as disclosed above, Mr. Zhu does not hold any directorships in any public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years, any other positions with the Company and other members of the Group, or any major appointments and professional qualifications.

Mr. Zhu does not have any relationship with any Directors, senior management, substantial or controlling shareholders of the Company and he has no interests in the shares of the Company which are required to be disclosed pursuant to Part XV of the SFO.

Save as disclosed herein, there are no other matters relating to the appointment of Mr. Zhu that need to be brought to the attention of the shareholders and there is no information which is required to be disclosed pursuant to Rule 17.50(2)(h) to (v) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited.

Mr. Zhu has entered into a service contract with the Company in relation to his appointment as an independent non-executive director of the Company for a term commencing on 24 April 2019 until the date of the next annual general meeting of the Company (the “**Term**”). His aggregate remuneration during the Term shall be RMB25,000, which was determined with reference to his duties, responsibilities as well as the Company’s remuneration policy and the market benchmark.

Trading in the shares of the Company has been suspended with effect from 9am on 27 September 2018, and will continue to be suspended until further notice.

By Order of the Board
Baytacare Pharmaceutical Co., Ltd.*
Executive Director
Cui Bingyan

Beijing, People’s Republic of China, 24 April 2019

As at the date of this announcement, the executive Directors are Cui Bingyan, Fang Yao and Guo Aiqun; the non-executive Directors are Shi Peng and Cao Yang; and the independent non-executive Directors are Chen Youfang and Zhu Tianxiang.

This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing Securities on GEM of The Stock Exchange of Hong Kong Limited for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the “Latest Company Announcements” page of the website of GEM at www.hkgem.com for at least 7 days from the date of the publication and the Company’s website at www.baytacare.com from the date of this announcement.

* for identification purposes only